Drug reference

Brentuximab

Monoclonal Antibody · Antineoplastic

Also known as Brentuximab vedotin

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid unless potential benefit outweighs risk (toxicity in animal studies).

FDA category + note

Mechanism

Brentuximab vedotin is an antibody-drug conjugate that targets CD30, a cell surface marker expressed on anaplastic large T-cell lymphomas and Reed-Sternberg cells in Hodgkin lymphoma. It consists of a chimeric IgG1 antibody linked to monomethylauristatin E (MMAE), a potent microtubule-disrupting agent. Upon binding to CD30, the complex is internalized, and MMAE is proteolytically cleaved, leading to cell cycle arrest and apoptosis of the cancer cells.

Indications

CD30 positive Hodgkin lymphoma (specialist use only)Systemic anaplastic large cell lymphoma (specialist use only)CD30 positive cutaneous T-cell lymphoma (specialist use only)Hodgkin lymphoma after failure of autologous stem cell transplantation or after failure of at least two previous chemotherapy regimensSystemic anaplastic large cell lymphoma after failure of at least one previous multiagent chemotherapy regimen

Dosing

Adult: l INDICATIONS AND DOSE CD30 positive Hodgkin lymphoma (specialist use only) | Systemic anaplastic large cell lymphoma (specialist use only) | CD30 positive cutaneous T-cell lymphoma (specialist use only) ▶ BY INTRAVENOUS INFUSION ▶ Adult: (consult product literature) Elevated BMI—risk of hyperglycaemia . high tumour burden—risk of tumour lysis syndrome .…

Side effects

Common

Abdominal painalopeciaanaemiaarthralgiaback painchillsconstipationcoughdiarrhoeadizzinessdyspnoeafatiguefeverhyperglycaemiaincreased risk of infectioninfusion related reactionmyalgianauseanerve disordersneutropeniaskin reactionsthrombocytopeniavomitingweight decreased

Serious